Drug Type Biological products |
Synonyms BMS 986315 |
Target |
Mechanism NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization NeuroTherapia, Inc.Startup |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Non-Small Cell Lung Cancer | Phase 2 | US | 27 Nov 2023 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | AU | 27 Nov 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 14 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CA | 14 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | MX | 14 Jul 2020 | |
Neuralgia | Phase 1 | US | NeuroTherapia, Inc.Startup | 10 Oct 2019 |